Neuroimmunology Program - IDIBAPS

Publications

  • Influence of corpus callosum damage on cognition and physical disability in multiple sclerosis: a multimodal study.

    Llufriu S, Blanco Y, Martinez-Heras E, Casanova-Molla J, Gabilondo I, Sepulveda M, Falcon C, Berenguer J, Bargallo N, Villoslada P, Graus F, Valls-Sole J, Saiz A. Influence of corpus callosum damage on cognition and physical disability in multiple sclerosis: a multimodal study. PLoS One. 2012;7(5):e37167. doi: 10.1371/journal.pone.0037167. Epub 2012 May 14. PubMed PMID: 22606347; PubMed Central PMCID: PMC3351399.

  • Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis

    Llufriu S, Sepúlveda M, Blanco Y, Marín P, Moreno B, Berenguer J, Gabilondo I, Martínez-Heras E, Sola-Valls N, Arnaiz JA, Andreu EJ, Fernández B, Bullich S, Sánchez-Dalmau B, Graus F, Villoslada P, Saiz A. Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis. PLoS One. 2014 Dec 1;9(12):e113936. doi: 10.1371/journal.pone.0113936. eCollection
    2014. PubMed PMID: 25436769; PubMed Central PMCID: PMC4250058.

  • Intense immunosuppression for the treatment of an immune reconstitution inflammatory syndrome-like exacerbation after natalizumab withdrawal: a case report.

    Sepúlveda M, Llufriu S, Blanco Y, Solà-Valls N, La Puma D, Berenguer J, Villoslada P, Saiz A. Intense immunosuppression for the treatment of an immune reconstitution inflammatory syndrome-like exacerbation after natalizumab withdrawal: a case report. J Neurol. 2015 Jan;262(1):219-21. doi: 10.1007/s00415-014-7574-6. Epub 2014 Nov 20. PubMed PMID: 25408366.

  • MRI characteristics of neuromyelitis optica spectrum disorder: an international update

    Kim HJ, Paul F, Lana-Peixoto MA, Tenembaum S, Asgari N, Palace J, Klawiter EC, Sato DK, de Seze J, Wuerfel J, Banwell BL, Villoslada P, Saiz A, Fujihara K, Kim SH; Guthy-Jackson Charitable Foundation NMO International Clinical Consortium & Biorepository. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology. 2015 Mar 17;84(11):1165-73. doi:
    10.1212/WNL.0000000000001367. Epub 2015 Feb 18. Review. PubMed PMID: 25695963; PubMed Central PMCID: PMC4371410.

  • Long-term follow-up of immunotherapy-unresponsive recurrent tumefactive demyelination

    La Puma D, Llufriu S, Sepúlveda M, Blanco Y, Ribalta T, Graus F, Saiz A. Long-term follow-up of immunotherapy-unresponsive recurrent tumefactive demyelination. J Neurol Sci. 2015 May 15;352(1-2):127-8. doi: 10.1016/j.jns.2015.03.038. Epub 2015 Mar 31. PubMed PMID: 25863778.

  • Walking function in clinical monitoring of multiple sclerosis by telemedicine

    Sola-Valls N, Blanco Y, Sepúlveda M, Llufriu S, Martínez-Lapiscina EH, La Puma
    D, Graus F, Villoslada P, Saiz A. Walking function in clinical monitoring of
    multiple sclerosis by telemedicine. J Neurol. 2015 Jul;262(7):1706-13. doi:
    10.1007/s00415-015-7764-x. Epub 2015 May 10. PubMed PMID: 25957639.4: 

  • Improved Framework for Tractography Reconstruction of the Optic Radiation

    Martínez-Heras E, Varriano F, Pr?kovska V, Laredo C, Andorrà M, Martínez-Lapiscina EH, Calvo A, Lampert E, Villoslada P, Saiz A, Prats-Galino A,  Llufriu S. Improved Framework for Tractography Reconstruction of the Optic Radiation. PLoS One. 2015 Sep  6;10(9):e0137064. doi: 10.1371/journal.pone.0137064. eCollection 2015. PubMed PMID: 26376179; PubMed Central PMCID: PMC4573981.

  • Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus.

    Sepúlveda M, Armangué T, Sola-Valls N, Arrambide G, Meca-Lallana JE, Oreja-Guevara C, Mendibe M, Alvarez de Arcaya A, Aladro Y, Casanova B, Olascoaga J, Jiménez-Huete A, Fernández-Fournier M, Ramió-Torrentà L, Cobo-Calvo A, Viñals M, de Andrés C, Meca-Lallana V, Cervelló A, Calles C, Rubio MB, Ramo-Tello C, Caminero A, Munteis E, Antigüedad AR, Blanco Y, Villoslada P, Montalban X, Graus F, Saiz A. Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus. Neurol Neuroimmunol Neuroinflamm. 2016 Apr 14;3(3):e225

  • Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes.

    Sepúlveda M, Armangue T, Martinez-Hernandez E, Arrambide G, Sola-Valls N, Sabater L, Téllez N, Midaglia L, Ariño H, Peschl P, Reindl M, Rovira A, Montalban X, Blanco Y, Dalmau J, Graus F, Saiz A. Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes. J Neurol. 2016 Jul;263(7):1349-60.

  • Usefulness of optical coherence tomography to distinguish optic neuritis associated with AQP4 or MOG in neuromyelitis optica spectrum disorders.

    Martinez-Lapiscina EH, Sepulveda M, Torres-Torres R, Alba-Arbalat S, Llufriu S, Blanco Y, Guerrero-Zamora AM, Sola-Valls N, Ortiz-Perez S,Villoslada P, Sanchez-Dalmau B, Saiz A. Usefulness of optical coherence tomography to distinguish optic neuritis associated with AQP4 or MOG in neuromyelitis optica spectrum disorders. Ther Adv Neurol Disord. 2016 Sep;9(5):436-40. doi: 10.1177/1756285616655264. Epub 2016 Aug 15. PMID: 27582898 PMCID: PMC4994783 

Research